Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 143Carcinoma, Neuroendocrine 56Thyroid Cancer, Papillary 54Pheochromocytoma 50Thyroid Neoplasms 41Paraganglioma 41Pituitary Neoplasms 37Adrenocortical Carcinoma 31Neoplasms 30Multiple Endocrine Neoplasia Type 1 29Gastro-enteropancreatic neuroendocrine tumor 29Thyroid Carcinoma, Anaplastic 23Small Cell Lung Carcinoma 21Lung Neoplasms 21Carcinoid Tumor 20Sarcoma 19Breast Neoplasms 19Neoplasm Metastasis 18Carcinoma, Non-Small-Cell Lung 18Adenoma, Islet Cell 18Melanoma 17Carcinoma, Hepatocellular 17Prostatic Neoplasms 15Pancreatic Neoplasms 15Ovarian Neoplasms 15Neuroblastoma 15Colorectal Neoplasms 15Carcinoma, Renal Cell 15Adrenal Gland Neoplasms 15Adenocarcinoma, Follicular 15

Interventions

11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Adenosquamous × Endocrine × 1 year × Clear all
NCT05988918 2026-05-14

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
17 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Somatostatinoma, Carcinoma, Adenosquamous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡